35241-23-7

Basic information

• Product Name: 6,7-DIMETHOXY-2-METHYLQUINAZOLIN-4-OL
• Synonyms: 6,7-DIMETHOXY-2-METHYLQUINAZOLIN-4-OL;6,7-diMethoxy-2-Methylquinazolin-4(3H)-one;NSC 338200;6,7-Dimethoxy-2-methyl-1H-quinazolin-4-one
• CAS NO: 35241-23-7
• Molecular Formula: C₁₁H₁₂N₂O₃
• Molecular Weight: 220.23
• Mol File: 35241-23-7.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 377.6°C at 760 mmHg
• Flash Point: 182.1°C
• Appearance: /
• Density: 1.29
• Vapor Pressure: 6.69E-06mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 6,7-DIMETHOXY-2-METHYLQUINAZOLIN-4-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7-DIMETHOXY-2-METHYLQUINAZOLIN-4-OL(35241-23-7)
• EPA Substance Registry System: 6,7-DIMETHOXY-2-METHYLQUINAZOLIN-4-OL(35241-23-7)

Safety Data

• Hazardous Substances Data: 35241-23-7(Hazardous Substances Data)

Usage

General Description

6,7-DIMETHOXY-2-METHYLQUINAZOLIN-4-OL, also known as DMQ, is a synthetic compound with potential applications in pharmaceuticals and research. It belongs to the quinazoline family and contains methoxy and methyl groups at specific locations on the quinazoline ring. DMQ has been studied for its potential anti-inflammatory, anticancer, and antimicrobial properties. In addition, it has been investigated as a potential drug candidate for various diseases, including cancer and Alzheimer's. DMQ's unique chemical structure and potential pharmacological activity make it an interesting compound for further research and development in the pharmaceutical industry.

InChI:InChI=1/C11H12N2O3/c1-6-12-8-5-10(16-3)9(15-2)4-7(8)11(14)13-6/h4-5H,1-3H3,(H,12,13,14)

Upstream product

• 6286-65-3 6,7-dimethoxy-2-methyl-4H-benzo[d] [1,3]oxazin-4-one 
• 92340-02-8 C₂₂H₂₂N₄O₄S₂ 
• 66299-70-5 6,7-dimethoxy-2-methylquinazoline-4(3H)-thione 
• 26759-46-6 methyl 2-amino-4,5-dimethoxybenzoate 
• 75-05-8 acetonitrile 
• 108-24-7 acetic anhydride 
• 5653-40-7 2-Amino-4,5-dimethoxybenzoic acid 
• 145352-75-6 2-acetamido-4,5-dimethoxybenzoic acid 
• 20323-74-4 2-carboethoxy-4,5-dimethoxyaniline 
• 73357-18-3 (4,5-dimethoxy-2-nitrophenyl)acetic acid 
• 100905-33-7 ethyl 2-nitro-4,5-dimethoxybenzoate 
• 61203-48-3 2-iodo-4,5-dimethoxybenzoic acid 
• 124-42-5 acetamidine hydrochloride 
• 6286-46-0 2-bromo-4,5-dimethoxybenzoic acid 

Downstream Products

• 50377-49-6 4-chloro-6,7-dimethoxy-2-methylquinazoline 
• 1448676-47-8 6,7-dimethoxy-4-(4-(2-methoxyphenyl)piperazin-1-yl)-2-methylquinazoline 
• 127033-39-0 6,7-Dimethoxy-2-((E)-styryl)-3H-quinazolin-4-one 

Relevant articles and documents

Design, synthesis and anticancer evaluation of structurally modified substituted aryl-quinazoline derivatives as anticancer agents

A new library of structurally modified aryl quinazoline-isoxazole (12a–j) derivatives have been designed, synthesized and characterized by 1HNMR, 13CNMR and mass spectral data. Further these compounds were evaluated for anticancer applications against four human cancer cell lines including PC3, DU-145 (prostate cancer), A549 (lung cancer) and MCF-7 (breast cancer) by utilizing the MTT assay. The results were compared with etoposide which was used as positive control. Most of the compounds showed good to moderate anticancer activities against the four cancer cell lines. Among them, compounds 12a, 12b, 12c, 12d and 12j exhibited more potent activities. Further, molecular docking studies were carried out for all synthesized compounds against the cancer targets Selective Human Androgen Receptor (PDB ID: 3V49) and Abl-Tyrosine kinase (PDB ID: 1IEP). All the docked ligands have exhibited good binding interactions with the targeted protein.

Cobalt-Catalyzed Tandem Transformation of 2-Aminobenzonitriles to Quinazolinones Using Hydration and Dehydrogenative Coupling Strategy

A tandem synthesis of quinazolinones from 2-aminobenzonitriles is demonstrated here by using an aliphatic alcohol-water system. For this transformation, a cheap and easily available cobalt salt and P(CH2CH2PPh2)3 (PP3) ligand were employed. The substrate scope, scalability, and synthesis of natural products exhibited the vitality of this protocol.

NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS

The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.